Abcam plc (ABCM) Stock

About Abcam plc

Abcam plc operates as a prominent life science enterprise, dedicated to the innovation, creation, and supply of crucial reagents and instruments. These fundamental resources are instrumental in supporting diverse scientific investigations, diagnostic applications, and the advancement of pharmaceutical drug discovery initiatives. Its comprehensive product portfolio features primary and secondary antibodies, conjugated antibodies paired with their respective kits, both singleplex and multiplex immunoassays, as well as a variety of proteins and peptides, including cytokines. Furthermore, the company provides edited cell lines, lysates, cellular activity kits, miRNA kits, biochemical compounds, and specialized tools for analyzing cell signaling pathways. Abcam serves a broad customer base, encompassing researchers and scientists within academic and institutional environments, alongside professionals at pharmaceutical, biotechnology, and diagnostic companies. The company boasts a global presence, conducting operations across the Americas, Europe, the Middle East, Africa, China, Japan, and the wider Asia Pacific region. Product distribution is primarily facilitated via its online platform. Founded in 1998, Abcam plc is headquartered in Cambridge, United Kingdom.

Abcam plc is headquartered in GB.

Abcam plc (ABCM) stock trades at $23.99 with a market capitalization of $5.52B. The stock is valued at a price-to-earnings (P/E) ratio of -482.24, price-to-book of 5.64, price-to-sales of 11.41. Over the past 52 weeks the stock has ranged between $12.48 and $25.32, and currently trades 5.3% below its 52-week high.

On profitability, Abcam plc generates a return on equity (ROE) of -1.23%, return on capital employed of 6.29%, an operating margin of 14.87%, a net profit margin of -2.35%.

Official website: www.abcam.com